pancreas tumor
Recently Published Documents


TOTAL DOCUMENTS

71
(FIVE YEARS 20)

H-INDEX

10
(FIVE YEARS 1)

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 376
Author(s):  
Natália Alves ◽  
Megan Schuurmans ◽  
Geke Litjens ◽  
Joeran S. Bosma ◽  
John Hermans ◽  
...  

Early detection improves prognosis in pancreatic ductal adenocarcinoma (PDAC), but is challenging as lesions are often small and poorly defined on contrast-enhanced computed tomography scans (CE-CT). Deep learning can facilitate PDAC diagnosis; however, current models still fail to identify small (<2 cm) lesions. In this study, state-of-the-art deep learning models were used to develop an automatic framework for PDAC detection, focusing on small lesions. Additionally, the impact of integrating the surrounding anatomy was investigated. CE-CT scans from a cohort of 119 pathology-proven PDAC patients and a cohort of 123 patients without PDAC were used to train a nnUnet for automatic lesion detection and segmentation (nnUnet_T). Two additional nnUnets were trained to investigate the impact of anatomy integration: (1) segmenting the pancreas and tumor (nnUnet_TP), and (2) segmenting the pancreas, tumor, and multiple surrounding anatomical structures (nnUnet_MS). An external, publicly available test set was used to compare the performance of the three networks. The nnUnet_MS achieved the best performance, with an area under the receiver operating characteristic curve of 0.91 for the whole test set and 0.88 for tumors <2 cm, showing that state-of-the-art deep learning can detect small PDAC and benefits from anatomy information.


2021 ◽  
pp. 17-26
Author(s):  
Hidekata Hontani ◽  
Tomoshige Shimomura ◽  
Tatsuya Yokota ◽  
Mauricio Kugler ◽  
Tomonari Sei ◽  
...  

Author(s):  
Natália Alves ◽  
Megan Schuurmans ◽  
Geke Litjens ◽  
Joeran S. Bosma ◽  
John Hermans ◽  
...  

Early detection improves prognosis in pancreatic ductal adenocarcinoma (PDAC) but is challenging as lesions are often small and poorly defined on contrast-enhanced computed tomography scans (CE-CT). Deep learning can facilitate PDAC diagnosis, however current models still fail to identify small (&amp;lt;2cm) lesions. In this study, state-of-the-art deep learning models were used to develop an automatic framework for PDAC detection, focusing on small lesions. Additionally, the impact of integrating surrounding anatomy was investigated. CE-CT scans from a cohort of 119 pathology-proven PDAC patients and a cohort of 123 patients without PDAC were used to train a nnUnet for automatic lesion detection and segmentation (nnUnet_T). Two additional nnUnets were trained to investigate the impact of anatomy integration: (1) segmenting the pancreas and tumor (nnUnet_TP), (2) segmenting the pancreas, tumor, and multiple surrounding anatomical structures (nnUnet_MS). An external, publicly available test set was used to compare the performance of the three networks. The nnUnet_MS achieved the best performance, with an area under the receiver operating characteristic curve of 0.91 for the whole test set and 0.88 for tumors &amp;lt;2cm, showing that state-of-the-art deep learning can detect small PDAC and benefits from anatomy information.


2021 ◽  
Vol 116 (1) ◽  
pp. S703-S704
Author(s):  
Abdul Rahman Al Armashi ◽  
Kanchi Patell ◽  
Francisco J. Somoza-Cano ◽  
Faris Hammad ◽  
Ricardo Celaya ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jia Yao ◽  
Man Yang ◽  
Lawrence Atteh ◽  
Pinyan Liu ◽  
Yongcui Mao ◽  
...  

AbstractPancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for treatment guidance is urgently required. This review focuses on pancreatic tumor organoids (PTOs), which can mimic the characteristics of the original tumor in vitro. As a powerful tool with several applications, PTOs represent a new strategy for targeted therapy in pancreatic cancer and contribute to the advancement of the field of personalized medicine.


Materials ◽  
2021 ◽  
Vol 14 (8) ◽  
pp. 2039
Author(s):  
Franz Steppeler ◽  
Dagmara Kłopotowska ◽  
Joanna Wietrzyk ◽  
Elżbieta Wojaczyńska

A library of 21 novel chiral 1,2,3-triazole-based 2-azabicycloalkane conjugates was designed and synthesized using the copper(I)-catalyzed click reaction. The obtained hybrids were assessed for their antiproliferative potency against three selected human cancer cell lines: Hs294T (melanoma), MIA PaCa-2 (pancreas tumor) and NCI-H1581 (lung tumor). The majority of the synthesized compounds demonstrated moderate to potent activity, and some of them appeared more selective than cisplatin, with selectivity index exceeding 9.


2021 ◽  
Author(s):  
OSCAR RICARDO PAREDES TORRES ◽  
Yoshikuni Kawaguchi ◽  
Eloy Ruiz Figueroa ◽  
Eduardo Payet Meza ◽  
Francisco Berrospi Espinoza

Abstract Purpose Pancreas tumors are extremely rare in pediatric and adolescent patients. Surgical resection is the mainstay of treatment; however, the data is limited with respect to morbidity and mortality. We aimed to evaluate short- and long-term outcomes of pediatric and adolescent patients who underwent surgical resection of pancreatic tumors. Methods Patients \(\le\) 18 years old who underwent resection of pancreas tumor at the National Institute of Neoplastic Diseases INEN during 2000–2020 were included. Results Thirty-four patients were diagnosed; 28 patients were female and 6 were male. The median age was 13.4 years old. Histological diagnosis was solid pseudopapillary neoplasm (SPN) (n = 29,85.3%), pancreatoblastoma (n = 3), neuroendocrine carcinoma (n = 1), and insulinoma (n = 1). No patient experienced postoperative mortality and 15 (44.1%) patients developed postoperative complications including pancreatic fistula as the most frequent. Under a median follow-up period of 33.8 (0.5–138) months, 4 (11.8%) patients died. Of the 29 patients with SPN, the 3-and-5-year OS was 100% and 83.1%, respectively. Conclusions SPN was the most frequent cause of surgical treatment for pediatric and adolescent patients in the high-volume cancer center in Peru and was associated with favorable survival. Pancreaticoduodenectomy was safely performed in this patient group with acceptable morbidity and zero mortality.


2021 ◽  
Author(s):  
Weiwei Li ◽  
Gregory C. Wilson ◽  
Magdalena Bachmann ◽  
Jiang Wang ◽  
Andrea Mattarei ◽  
...  

AbstractThe mitochondrial voltage-gated potassium channel, Kv1.3, has been emerged as an attractive oncologic target but its function in pancreas cancer (PDAC) is unknown. In this study we evaluated tissue expression of Kv1.3 in resected PDAC from 55 patients and tumor inhibition in orthotopic mouse models using the recently developed Kv1.3 inhibitors PCARBTP and PAPTP. Immunohistochemistry of 55 human PDAC specimens showed that all tumors expressed Kv1.3 with 60% of tumor specimens having high Kv1.3 expression. In pancreas tumor models (Pan02 cells injected into C57BL/6 mice), PCARBTP and PAPTP treatment resulted in tumor reductions of 87% and 70%, respectively. When combined with gemcitabine/abraxane, this increased to 95% and 80% without resultant organ toxicity. In vivo models indicated PCARBTP-mediated cell death occurred through the p38-MAPK pathway. In vitro-generated resistant clones to PCARBTP escaped cell death through upregulation of the anti-oxidant system as determined using SWATH-MS analysis. These data show Kv1.3 is highly expressed in resected human PDAC and the use of novel mitochondrial Kv1.3 inhibitors combined with cytotoxic chemotherapies might be novel, effective treatment for PDAC.


2021 ◽  
Vol 78 ◽  
pp. 214-218
Author(s):  
Le Tuan Linh ◽  
Thieu-Thi Tra My ◽  
Bui Van Lenh ◽  
Tran-Van Giang ◽  
Luong Viet Bang ◽  
...  

2020 ◽  
Vol 66 (4) ◽  
Author(s):  
Carlos Rafael Lima Monção ◽  
Levindo Tadeu Freitas de Figueiredo Dias ◽  
Cecília Barbosa Alcântara ◽  
Thereza Cristina Abreu Versiani ◽  
Autieri Alves Correia
Keyword(s):  

Introdução: A neoplasia pseudopapilífera sólida de pâncreas (tumor de Frantz) é muito rara e representa menos de 1% de todos os tumores pancreáticos. Relato do caso: Paciente do sexo feminino, 48 anos, internada para investigação de massa intra-abdominal de etiologia a esclarecer. Foi submetida a tratamento cirúrgico com sucesso na ressecção tumoral e não apresentou complicações no pós-operatório. Os pacientes usualmente tornam-se sintomáticos somente após longos períodos de evolução, quando então apresentam desconforto ou dor abdominal, ou a palpação de massas abdominais no exame físico. Para o diagnóstico, são necessários exames de imagem como ultrassonografia e tomografia computadorizada, que geralmente evidenciam volumosas massas heterogêneas intra-abdominais. É necessária a confirmação com estudo anatomopatológico e comumente estas possuem características histológicas compatíveis com tumores de baixo grau de malignidade. A ressecção cirúrgica é o tratamento recomendado e mesmo os tumores de grandes dimensões possuem chances de curas consideráveis, se for possível obter margens cirúrgicas livres. Sabe-se que a ressecção tumoral completa é associada a longos períodos de sobrevida. Conclusão: A neoplasia pseudopapilífera sólida de pâncreas (tumor de Frantz), apesar de rara, deve ser considerada no diagnóstico diferencial de tumores de pâncreas, já que o tratamento cirúrgico apresenta boas chances de cura mesmo em tumores de grandes dimensões.


Sign in / Sign up

Export Citation Format

Share Document